New Jersey Urology, LLC

njurology.com

New Jersey Urology (NJU), the largest single-specialty urology group in the U.S., provides integrated urological care with a special emphasis on prostate cancer. We are dedicated to providing excellence in the care we provide, utilizing state-of-the-art technologies and employing highly-qualified, compassionate professionals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

news image

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

news image

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

CELL AND GENE THERAPY

ULTIMA GENOMICS AND OLINK COLLABORATE TO DEVELOP SOLUTION FOR HIGH-THROUGHPUT PROTEOMICS

Ultima Genomics | June 09, 2022

news image

Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable ...

Read More
news image

RESEARCH

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More
news image

INDUSTRIAL IMPACT

CYCLICA LAUNCHES PERTURBA THERAPEUTICS, A SPIN OUT FROM THE UNIVERSITY OF TORONTO, CREATING THE NEXT-GENERATION ONCOLOGY BIOTECH

Cyclica Inc. | February 10, 2022

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Read More
news image

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

CELL AND GENE THERAPY

ULTIMA GENOMICS AND OLINK COLLABORATE TO DEVELOP SOLUTION FOR HIGH-THROUGHPUT PROTEOMICS

Ultima Genomics | June 09, 2022

Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable ...

Read More